Ceritinib (LDK378)

For research use only. Not for use in humans.

目录号：S7083

CAS No. 1032900-25-6

Ceritinib (LDK378)是一种有效的ALK抑制剂，在无细胞试验中IC50为0.2 nM。Ceritinib (LDK378)还可抑制IGF-1R、InsR、STK22D和FLT3对应的IC50值分别为8 nM、7 nM、23 nM和60 nM。Phase 3。

规格

价格

库存

购买数量

5mg	RMB 1182.86	现货
50mg	RMB 3868.47	现货
200mg	RMB 10720.71	现货
大包装	有超大折扣

大剂量询单有大折扣!

今日订购，明日送达，全国免运费！

全国免费电话：400-668-6834 | Email：info@selleck.cn

客户使用Selleck生产的Ceritinib (LDK378)发表文献64篇：

Nature, 2019, 10.1038/s41586-019-1472-0

PubMed: 31391581 ( click the link to review the publication )

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Cell, 2019, 36(2):179-193

PubMed: 28162770 ( click the link to review the publication )

Nat Med, 2015, 21(9):1038-47

PubMed: 26301689 ( click the link to review the publication )

Cancer Cell, 2015, 27(3):397-408

PubMed: 25759024 ( click the link to review the publication )

Nat Med, 2014, 20(9):1027-34

PubMed: 25173427 ( click the link to review the publication )

EMBO Mol Med, 2020, e11099

PubMed: 32558295 ( click the link to review the publication )

Clin Cancer Res, 2020, 8

PubMed: 32269053 ( click the link to review the publication )

Genome Med, 2020, 18;12(1):17

PubMed: 32070411 ( click the link to review the publication )

Cell Rep, 2020, 31(12):107800

PubMed: 32579927 ( click the link to review the publication )

Oncogene, 2020, 39(1):151-163

PubMed: 31462708 ( click the link to review the publication )

Cancers (Basel), 2020, 24;12(4) pii: E1054

PubMed: 32344689 ( click the link to review the publication )

Cancers (Basel), 2020, 26;12(4)

PubMed: 32224911 ( click the link to review the publication )

Cancer Discov, 2020, 1 pii: CD-19-1030

PubMed: 32238360 ( click the link to review the publication )

Sci Rep, 2020, 10(1):218

PubMed: 31937834 ( click the link to review the publication )

Acta Pharmacol Sin, 2020, 10.1038/s41401-020-00513-3

PubMed: 32918045 ( click the link to review the publication )

Oncol Rep, 2020, 44(6):2581-2594

PubMed: 33125153 ( click the link to review the publication )

Hum Cell, 2020, 10.1007/s13577-020-00420-z

PubMed: 32870449 ( click the link to review the publication )

Cancer Cell, 2020, 38(1):44-59.e9

PubMed: 32663469 ( click the link to review the publication )

J Thorac Oncol, 2020, 15(5):752-765

PubMed: 31972351 ( click the link to review the publication )

Nat Commun, 2019, 10(1):4343

PubMed: 31554817 ( click the link to review the publication )

EMBO Mol Med, 2019, 10.15252/emmm.201910581

PubMed: 31633304 ( click the link to review the publication )

Cell Syst, 2019, 8(2):97-108

PubMed: 30797775 ( click the link to review the publication )

Oncogene, 2019, 101038/s41388-019-1136-4

PubMed: 31804622 ( click the link to review the publication )
Cancers (Basel), 2019, 11(1)E104

PubMed: 30658414 ( click the link to review the publication )

Int J Mol Sci, 2019, 20(17)

PubMed: 31480400 ( click the link to review the publication )

Sci Rep, 2019,

PubMed: 31882684 ( click the link to review the publication )

Biochem J, 2019, 10.1042/BCJ20190106

PubMed: 31341009 ( click the link to review the publication )

Invest New Drugs, 2019, 10.1007/s10637-019-00795-3

PubMed: 31124056 ( click the link to review the publication )

Invest New Drugs, 2019, 10.1007/s10637-019-00802-7

PubMed: 31177400 ( click the link to review the publication )

Cancer Immunol Res, 2019,

PubMed: 31540894 ( click the link to review the publication )

Blood, 2018, 131(14):1576-1586

PubMed: 29437595 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(17):4162-4174

PubMed: 29776956 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(23):6066-6077

PubMed: 30061362 ( click the link to review the publication )

Cancer Res, 2018, 78(24):6866-6880

PubMed: 30322862 ( click the link to review the publication )

Cell Death Differ, 2018, 25(12):2053-2070

PubMed: 29515255 ( click the link to review the publication )

Sci Signal, 2018, 11(557)

PubMed: 30459283 ( click the link to review the publication )

Cell Physiol Biochem, 2018, 46(6):2487-2499

PubMed: 29742496 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(11-:2271-2284

PubMed: 30135214 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(1):222-231

PubMed: 29054983 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(1):73-83

PubMed: 29133622 ( click the link to review the publication )

Mol Pharm, 2018, 15(5):1892-1900

PubMed: 29595984 ( click the link to review the publication )

Cancer Discov, 2018, 8(6):714-729

PubMed: 29650534 ( click the link to review the publication )

Cancer Chemother Pharmacol, 2018, 82(2):251-263

PubMed: 29855693 ( click the link to review the publication )

Onco Targets Ther, 2018, 11:8201-8209

PubMed: 30568455 ( click the link to review the publication )

Oncotarget, 2018, 9(43-:27242-27255

PubMed: 29930762 ( click the link to review the publication )

Sci Transl Med, 2017, 14;9(394):eaah6144

PubMed: 28615362 ( click the link to review the publication )

Cell Rep, 2017, 21(11):3298-3309

PubMed: 29241554 ( click the link to review the publication )
J Pathol, 2017, 243(3):307-319

PubMed: 28741662 ( click the link to review the publication )

Arch Toxicol, 2017, 91(8):2921-2938

PubMed: 28032146 ( click the link to review the publication )

Cancer Sci, 2017,

PubMed: 27783866 ( click the link to review the publication )

Anticancer Drugs, 2017, 28(10):1118-1125

PubMed: 29045271 ( click the link to review the publication )

Oncotarget, 2017, 8(35):58771-58780

PubMed: 28938595 ( click the link to review the publication )

J Pathol, 2016, 238(4):543-9

PubMed: 26606880 ( click the link to review the publication )

Oncoimmunology, 2016, 5(3):e1094598

PubMed: 27141355 ( click the link to review the publication )

Cell Physiol Biochem, 2016, 40(5):1129-1140

PubMed: 27960155 ( click the link to review the publication )

Mol Oncol, 2016, 10(4):601-9

PubMed: 26639656 ( click the link to review the publication )

Cancer Discov, 2016, 6(10):1118-1133

PubMed: 27432227 ( click the link to review the publication )

Sci Rep, 2016, 6:33710

PubMed: 27641368 ( click the link to review the publication )

Sci Rep, 2016, 10.1038/srep24817

PubMed: 27102549 ( click the link to review the publication )

Cell Res, 2015, 10.1038/cr.2015.16

PubMed: 25656847 ( click the link to review the publication )

Mol Oncol, 2015, 10.1016/j.molonc.2015.11.007

PubMed: 26639656 ( click the link to review the publication )

Oncotarget, 2015, 6(42):44643-59

PubMed: 26556876 ( click the link to review the publication )

Biochem Biophys Res Commun, 2014, 454(4):566-571

PubMed: 25450694 ( click the link to review the publication )

产品安全说明书

ALK抑制剂选择性比较

生物活性

产品描述

特性

不与c-Met交叉反应，对体内葡萄糖稳态比TAE684效果好，有效作用于 Crizotinib复发的肿瘤。

靶点

ALK ^[1] (Cell-free assay)	Insulin Receptor ^[1] (Cell-free assay)	IGF-1R ^[1] (Cell-free assay)	STK22D ^[1] (Cell-free assay)	FLT3 ^[1] (Cell-free assay)
0.2 nM	7 nM	8 nM	23 nM	60 nM

体外研究

LDK378作用于Ba/F3-NPM-ALK和Karpas290细胞，具有显著的抗增殖活性，IC50分别为26.0 nM 和 22.8 nM,作用于Ba/F3-Tel-InsR 和Ba/F3-WT细胞，IC50分别为319.5 nM 和 2477 nM。^[1]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
Parental(+IL3)	MmjmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MWi3NkBp	NUTxN5FZTE2VTx?=	MlL0TWM2OD1zNUi2JOKyKDF5MzDuUS=>	MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTd2OUCzOEc,OjV5NEmwN\|Q9N2F-
WT 70	MoPBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M2\PdVczKGh?	MnjGSG1UVw>?	M1rPd2lEPTB;MkGgxtEhQCCwTR?=	M1y5S\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3N{S5NFM1Lz5{NUe0PVA{PDxxYU6=
G1128S 1022	Mk\JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MkfMO\|IhcA>?	MW\EUXNQ	M{PTSGlEPTB;MUCyJOKyKDN6IH7N	NFzrO5I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUe0PVA{PCd-MkW3OFkxOzR:L3G+
C1156F 1293	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		Mom0O\|IhcA>?	Mk\OSG1UVw>?	MoLFTWM2OD1{MUegxtEhOTF3IH7N	MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTd2OUCzOEc,OjV5NEmwN\|Q9N2F-
I1171N 519	M1GzSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NUXFbXZtPzJiaB?=	MnTpSG1UVw>?	NX;XSlI4UUN3ME2xPFchyrFiOEegcm0>	MnvzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV5NEmwN\|QoRjJ3N{S5NFM1RC:jPh?=
I1171T 445	NFG5dotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NUnwZ5RHPzJiaB?=	NEDOdYpFVVOR	NGPFPG9KSzVyPUiyJOKyKDF{IH7N	Moi4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV5NEmwN\|QoRjJ3N{S5NFM1RC:jPh?=
F1174I 184	M3ewd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M2L4XVczKGh?	NWLNeoFKTE2VTx?=	NEjWUmJKSzVyPUGzJOKyKDBwMTDuUS=>	MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTd2OUCzOEc,OjV5NEmwN\|Q9N2F-
N1178H 169	M4mwU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MYK3NkBp	MnfISG1UVw>?	MVvJR\|UxRTR{INMxJFYhdk1?	MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTd2OUCzOEc,OjV5NEmwN\|Q9N2F-
E1210K 748	NXvsOoZJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MVm3NkBp	NUC3cZB[TE2VTx?=	M4LyPWlEPTB;MUi3JOKyKDh2IH7N	MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTd2OUCzOEc,OjV5NEmwN\|Q9N2F-
C1156F/D1203N 2809	MnXGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M2O5XlczKGh?	MVXEUXNQ	MoTkTWM2OD1{NUSgxtEhQTlibl2=	NVfNdGx{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW3OFkxOzRpPkK1O\|Q6ODN2PD;hQi=>
Ba/F3 NA WT	NIrUO2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MV[3NkBp		M3LaRWlEPTB;MD6wNlAh\|ryP	NXfaWGhzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW3Nlc1ODBpPkK1O\|I4PDByPD;hQi=>
Ba/F3 NA C1156Y	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M3PnSVczKGh?		MnjOTWM2OD1yLkC3NUDPxE1?	MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTd{N{SwNEc,OjV5Mke0NFA9N2F-
Ba/F3 NA L1196M	NXXT[nZIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NGXpeZk4OiCq		M4npTmlEPTB;MD6wOFIh\|ryP	Mo\4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV5Mke0NFAoRjJ3N{K3OFAxRC:jPh?=
Ba/F3 NA L1152R	MorWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MXS3NkBp		MnHrTWM2OD1yLkK4PEDPxE1?	MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTd{N{SwNEc,OjV5Mke0NFA9N2F-
Ba/F3 NA G1202R	M{XqcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MUK3NkBp		MofaTWM2OD1yLkK3O{DPxE1?	Mo\nQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV5Mke0NFAoRjJ3N{K3OFAxRC:jPh?=
Ba/F3 NA G1269A	NUjBfmlST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NIjLT204OiCq		MWfJR\|UxRTBwMEG5JO69VQ>?	NWrtPWN3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW3Nlc1ODBpPkK1O\|I4PDByPD;hQi=>
Ba/F3 NA S1206Y	M2jCN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NGXvVY04OiCq		MkHHTWM2OD1yLkCzO{DPxE1?	Mm[wQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV5Mke0NFAoRjJ3N{K3OFAxRC:jPh?=
Ba/F3 EA WT	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NEf5UYk4OiCq		Mk\pTWM2OD1yLkCyNUDPxE1?	NHHNeos9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUeyO\|QxOCd-MkW3Nlc1ODB:L3G+
Ba/F3 EA C1156Y	NFzEbYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NUHSXmppPzJiaB?=		M2e0WmlEPTB;MD6wNlYh\|ryP	MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTd{N{SwNEc,OjV5Mke0NFA9N2F-
Ba/F3 EA L1196M	NHPjb\|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NELDSZQ4OiCq		MXnJR\|UxRTBwMEG5JO69VQ>?	MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTd{N{SwNEc,OjV5Mke0NFA9N2F-
Ba/F3 EA L1152R	MlzyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M2LLW\|czKGh?		MYrJR\|UxRTBwMEm5JO69VQ>?	NFHyWG49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUeyO\|QxOCd-MkW3Nlc1ODB:L3G+
Ba/F3 EA G1202R	Ml;2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M1fKcVczKGh?		NUK5d5FqUUN3ME2wMlQ3PyEQvF2=	MkjFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV5Mke0NFAoRjJ3N{K3OFAxRC:jPh?=
Ba/F3 EA G1269A	MkXBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M1voW\|czKGh?		MXPJR\|UxRTBwMEOzJO69VQ>?	M1X3eVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3N{K3OFAxLz5{NUeyO\|QxODxxYU6=
Ba/F3 EA S1206Y	NIHWdGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NEPiWXo4OiCq		MlzaTWM2OD1yLkCzPEDPxE1?	MmLWQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV5Mke0NFAoRjJ3N{K3OFAxRC:jPh?=
BAF3	MXvBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		NXPa[494PzJiaILz		MnLXRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDtc5V{\SCEQV[zJINmdGy\|IHjhdoJwemmwZzDFUWw1NUGOSzDh[pRmeiB5MjDodpMh[nliU2LCJI9zKEOFS{igZZN{[XluIFnDOVAhRSByLkCxNFch\|ryPLh?=	MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTJ6OEm0NEc,Ojl{OEi5OFA9N2F-
NCI-H3122	MUTBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		MlXBO\|IhcHK\|		MWjBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE6FST3IN\|EzOiClZXzsd{Bi\nSncjC3NkBpenNiYomgR4VtdFSrdHXyMWdtdyCOdX3pcoV{[2WwdDDD[YxtKF[rYXLpcIl1gSCDc4PhfUwhTUN3MDC9JFAvODF3IN88UU4>	MmjzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ3NkiyPFkoRjJ4NU[4Nlg6RC:jPh?=
NCI-H2228	Mk\GS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		M{ezSVMh\GG7cx?=		MmrTS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gUmNKNUh{MkK4JINmdGy\|IHHmeIVzKDNiZHH5d{BjgSCudX3pcoV{[2WwY3WtZoF{\WRiQ3XscHRqfGW{LVfsc{Bie3OjeTygTWM2OCB;IECuNFE2KM7:TT6=	M{XTV\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NkK3O\|I2Lz5{OU[yO\|czPTxxYU6=
SU-DHL1	MVHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NVTOd41EOyCmYYnz		NXTUVWR5T3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hW1VvRFjMNUBk\WyuczDh[pRmeiB\|IHThfZMh[nlibIXtbY5me2OnbnPlMYJie2WmIFPlcIxVcXSncj3HcI8h[XO\|YYmsJGlEPTBiPTCwMlAyPSEQvF2u	M2nlVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NkK3O\|I2Lz5{OU[yO\|czPTxxYU6=
DFCI114	NGHFSY5CdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		NV;IcWJ5PzJiaILz		NIDjOGJCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFTGR2kyOTRiY3XscJMh\XiycnXzd4lv\yCHTVy0MWFNUyCJMUK2PWEhdXW2YX70JIFnfGW{IEeyJIhzeyCkeTDD[YxtXGm2ZYKtS4xwKEy3bXnu[ZNk\W62IFPlcIwhXmmjYnnsbZR6KEG\|c3H5MEBGSzVyIE2gNE4xOThizszNMi=>	NITzVWU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkW2PFI5QSd-Mk[1OlgzQDl:L3G+
HCC78	M3LkeWN6fG:2b4jpZ4l1gSCjc4PhfS=>		M4X2clczKGi{cx?=		NHvJTIREgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBJS0N5ODDj[YxteyCqYYLic5JqdmdiU1zDN\|RCOi2UT2OxJIF{e2W\|c3XkJIF{KHKnZIXjeIlwdiCrbjDj[YxtKHC{b3zp[oVz[XSrb36gZYZ1\XJiN{KgbJJ{KGK7IF3UWEBie3OjeTygTWM2OCB;IECuNFE5KM7:TT6=	NVK3eHlvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMke0O\|Q6OjVpPkK3OFc1QTJ3PD;hQi=>
KARPAS299	M37MNmN6fG:2b4jpZ4l1gSCjc4PhfS=>		Mnf5NkB1dyB\|IHThfZM>		M{HCSGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGtCWlCDU{K5PUBk\WyuczDh[pRmeiB{IITvJFMh\GG7czDifUBtfWOrZnXyZZNmKHKncH;yeIVzKGenbnWgZZN{[XluIFnDOVAhRSByLkCyNlgh\|ryPLh?=	MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzd2MkK1Nkc,OjN5NEKyOVI9N2F-
KARPAS299	NFjkfItEgXSxdH;4bYNqfHliYYPzZZk>				MVrDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDLRXJRSVN{OUmgZ4VtdHNiZYjwdoV{e2mwZzDOVG0uSUyNIH\1d4lwdiCpZX7lJIF{e2W\|c3XkJIF{KGe{b4f0bEBqdmirYnn0bY9vNCCLQ{WwJF0hOC5yMkK4JO69VS5?	MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh\|N{e5O{c,OjN6M{e3PVc9N2F-
NCI-H3122	NHfsfGZHfW6ldHnvckBie3OjeR?=		NVr5S\|BOPzJiaILz		MV;Jcohq[mm2aX;uJI9nKEWPTESg[pV{\WRiQVzLJIlvKGi3bXHuJG5EUS2KM{GyNkBk\WyuczDhd5Nme3OnZDDhd{Bk\WyuIHfyc5d1cCCrbnjpZol1cW:wIH3lZZN2emWmIHHmeIVzKDd{IHjyd{BjgSCVUlKgZZN{[XluIFPDOVAhRSByLkCyOUDPxE1w	MnjCQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd7MUWxOlkoRjJ5OUG1NVY6RC:jPh?=
BAF3	M1nDVmZ2dmO2aX;uJIF{e2G7		NIjFPGYzKHSxIEOg[IF6ew>?		Mlu4TY5pcWKrdHnvckBw\iCQUF2t[pV{\WRiQVzLJEh2dmuwb4fuJI9zcWerbjmg[ZhxemW\|c3XkJIlvKG2xdYPlJGJCTjNiY3XscJMh[W[2ZYKgNkB1dyB\|IHThfZMh[nlibIXjbYZmemG\|ZTDy[ZBwenSncjDn[Y5mKGG\|c3H5MEBKSzVyIE2gNE4xOjZizszNMi=>	NUHZdokzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO3OFIzPTJpPkKzO\|QzOjV{PD;hQi=>
BA/F3	NEXEcYdEgXSxdH;4bYNqfHliYYPzZZk>				M{DCcmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KG2xdYPlJGJCN0Z\|IHPlcIx{KGW6cILld5NqdmdiTmDNMWFNUyCodYPpc44h\2WwZTDhd5Nme3OnZDDhd{Boem:5dHigbY5pcWKrdHnvckwhUUN3MDC9JFAvODJ4IN88UU4>	MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh\|N{e5O{c,OjN6M{e3PVc9N2F-
KARPAS299	MVHBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		Mn2xO\|IhcHK\|		M4PVemFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iS1HSVGFUOjl7IHPlcIx{KGijcnLvdolv\yCQUF2tRWxMKGGodHXyJFczKGi{czDifUBOXFRiYYPzZZktKEmFNUCgQUAxNjB{NjFOwG0v	MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTF5NEiwPUc,OjlzN{S4NFk9N2F-
NCI-H2228	Ml3TRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		M1Tad\|czKGi{cx?=		NITqUJFCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF7DTU1JOjJ{ODDj[YxteyCqYYLic5JqdmdiRV3MOE1CVEtiYX\0[ZIhPzJiaILzJIJ6KE2WVDDhd5NigSxiSVO1NEA:KDBwMEK2JO69VS5?	NYC5XW83RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{CyNlMyOjBpPkOwNlI{OTJyPD;hQi=>
KARPAS299	M3TWfGN6fG:2b4jpZ4l1gSCjc4PhfS=>		NXnM[ZZPPzJiaILz		M4nrOGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGtCWlCDU{K5PUBk\WyuczDoZZJjd3KrbnegUnBONUGOSzDhd5Nme3OnZDDhd{Bz\WS3Y4Tpc44hcW5iY3XscEBxem:uaX\ldoF1cW:wIHHmeIVzKDd{IHjyd{BjgSCPVGSgZZN{[XluIFnDOVAhRSByLkCyO{DPxE1w	NGX6PFY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{S3OFkzPSd-Mke0O\|Q6OjV:L3G+
Ba/F3	MX7GeY5kfGmxbjDhd5NigQ>?		M2[xbVczKGi{cx?=		MlHHTY5pcWKrdHnvckBw\iCHTVy0MWFNUyCVMUKwOnkhdXW2YX70JEh2dmuwb4fuJI9zcWerbjmg[ZhxemW\|c3XkJIlvKG2xdYPlJGJiN0Z\|IHPlcIx{KGG\|c3Xzd4VlKGG\|IHPlcIwhfmmjYnnsbZR6KGGodHXyJFczKGi{czDifUBOXFNiYYPzZZktKEmFNUCgQUAxNjB\|MzFOwG0v	MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjV4OEK4PUc,OjZ3NkiyPFk9N2F-
NCI-H3122	NXXTWplNSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=				M1e1SGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4Sge4lt\CC2eYDlJIh2dWGwIF7DTU1JOzF{MjDj[YxteyxiQ1O1NEA:KDBwMEO4JO69VS5?	NIO5[VM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkKzOVk1PSd-Mk[yN\|U6PDV:L3G+
NCI-H3122	NHz4bo5HfW6ldHnvckBie3OjeR?=		NH;ab4k4OiCqcoO=		NYi1eZJYUW6qaXLpeIlwdiCxZjDFUWw1NUGOSzDpckBpfW2jbjDOR2kuUDNzMkKgZ4VtdHNiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iClZXzsJJBzd2yrZnXyZZRqd25iYX\0[ZIhPzJiaILzJIJ6KFOUQjDhd5NigSxiQ1O1NEA:KDBwMEO4JO69VS5?	NYLCU3VyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[5NlM3QTVpPkK2PVI{Pjl3PD;hQi=>
NCI-H3122	NWDSSZlzTnWwY4Tpc44h[XO\|YYm=		MmHUO\|IhcHK\|		Mnn5TY5pcWKrdHnvckBw\iCHTVy0MWFNUyCrbjDoeY1idiCQQ1mtTFMyOjJiY3XscJMh[XO\|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kBk\WyuIIDyc4xq\mW{YYTpc44h[W[2ZYKgO\|IhcHK\|IHL5JHNTSiCjc4PhfUwhS0N3MDC9JFAvODN6IN88UU4>	MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjl{M{[5OUc,OjZ7MkO2PVU9N2F-
NCI-H3122	NFmw[YpHfW6ldHnvckBie3OjeR?=		NFz0e2E4OiCqcoO=		M4P6dmlvcGmkaYTpc44hd2ZiRV3MOEBnfXOnZDDBUGshcW5iaIXtZY4hVkOLLVizNVIzKGOnbHzzJIF{e2W\|c3XkJIF{KGOnbHyg[5Jwf3SqIHnubIljcXSrb36gZYZ1\XJiN{KgbJJ{KGK7IGPSRkBie3OjeTygR2M2OCB;IECuNFM5KM7:TT6=	NXjMVm1vRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkizPFU2ODVpPkK4N\|g2PTB3PD;hQi=>
BA/F3	MXLGeY5kfGmxbjDhd5NigQ>?				NFK2eGVKdmirYnn0bY9vKG:oIFHMT{ApfW6tbn;3ckBwemmpaX6pJJRz[W6\|ZnXjeIVlKGmwIH3veZNmKEKDL1[zJINmdGy\|LDDJR\|UxKD1iMD6wOFA4KM7:TT6=	MkXPQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6M{e3PVcoRjJ\|OEO3O\|k4RC:jPh?=
Ba/F3	Mn\sSpVv[3Srb36gZZN{[Xl?		Ml;WO\|IhcHK\|		NILxdoJKdmirYnn0bY9vKG:oIIfpcIQhfHmyZTDFUWw1NUGOSzCoeY5sdm:5bjDvdolocW5rIHX4dJJme3OnZDDpckBud3W\|ZTDCZU9HOyClZXzsd{Bie3Onc4Pl[EBieyClZXzsJJZq[WKrbHn0fUBi\nSncjC3NkBpenNiYomgUXRUKGG\|c3H5MEBKSzVyIE2gNE4xPDFizszNMi=>	NXXuW5M5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[1OlgzQDlpPkK2OVY5Ojh7PD;hQi=>
Ba/F3	MWHGeY5kfGmxbjDhd5NigQ>?		MmjzO\|IhcHK\|		M{WwU2lvcGmkaYTpc44hd2Zid3ns[EB1gXCnIFXNUFQuSUyNIDj1cotvd3ewIH;ybYdqdiliZYjwdoV{e2WmIHnuJI1wfXOnIFLhM2Y{KGOnbHzzJIF{e2W\|c3XkJIF{KGOnbHygeoli[mmuaYT5JIFnfGW{IEeyJIhzeyCkeTDNWHMh[XO\|YYmsJGlEPTBiPTCwMlA1OSEQvF2u	NIDMPXQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkW2PFI5QSd-Mk[1OlgzQDl:L3G+
KARPAS299	M3f4[WFvfGmycn;sbYZmemG2aY\lJIF{e2G7		MYi3NkBpenN?		MUfBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEuDUmDBV\|I6QSClZXzsd{Bp[XKkb4LpcochVlCPLVHMT{Bi\nSncjC3NkBpenNiYomgUXRVKGG\|c3H5MEBKSzVyIE2gNE4xPDFizszNMi=>	MmTnQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzB{MkOxNlAoRjNyMkKzNVIxRC:jPh?=
BAF3	NHuzOFRCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		MojrO\|IhcHK\|		M37sdGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgcY92e2ViQlHGN{Bk\WyuczDoZZJjd3KrbnegSW1NPC2DTFugUFEyQT[PIH31eIFvfCCjZoTldkA4OiCqcoOgZpkhW1KEIH;yJGNEUzhiYYPzZZktKEmFNUCgQUAxNjB3NEmg{txONg>?	MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTJ6OEm0NEc,Ojl{OEi5OFA9N2F-
Ba/F3	MUTGeY5kfGmxbjDhd5NigQ>?		M2fQb\|czKGi{cx?=		NVKxcHpKUW6qaXLpeIlwdiCxZjDFUWw1NUGOSzDHNVI3QUFibYX0ZY51KCi3bnvuc5dvKG:{aXfpckkh\XiycnXzd4VlKGmwIH3veZNmKEKjL1[zJINmdGy\|IHHzd4V{e2WmIHHzJINmdGxidnnhZoltcXS7IHHmeIVzKDd{IHjyd{BjgSCPVGOgZZN{[XluIFnDOVAhRSByLkC1O{DPxE1w	NVj5SpY1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[1OlgzQDlpPkK2OVY5Ojh7PD;hQi=>
HCC78	MVvBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		M{fjT\|czKGi{cx?=		MVXBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEiFQ{e4JINmdGy\|IHjhdoJwemmwZzDTUGM{PEF{LWLPV\|Eh[W[2ZYKgO\|IhcHK\|IHL5JG1VXCCjc4PhfUwhUUN3MDC9JFAvODV6IN88UU4>	MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTF5NEiwPUc,OjlzN{S4NFk9N2F-
HCC78	MXrBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		M2XOV\|czKGi{cx?=		NWLhT3B3SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDIR2M4QCClZXzsd{Bp[XKkb4LpcochW0yFM{TBNk1TV1NzIHHmeIVzKDd{IHjyd{BjgSCPVGSgZZN{[XluIFnDOVAhRSByLkC1PEDPxE1w	MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODJ{M{GyNEc,OzB{MkOxNlA9N2F-
Ba/F3	M4nDTWZ2dmO2aX;uJIF{e2G7		MYS3NkBpenN?		NV3EfY5XUW6qaXLpeIlwdiCxZjDFUWw1NUGOSzDMNVE6Pk1ibYX0ZY51KCi3bnvuc5dvKG:{aXfpckkh\XiycnXzd4VlKGmwIH3veZNmKEKjL1[zJINmdGy\|IHHzd4V{e2WmIHHzJINmdGxidnnhZoltcXS7IHHmeIVzKDd{IHjyd{BjgSCPVGOgZZN{[XluIFnDOVAhRSByLkC2OEDPxE1w	MmKxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ3NkiyPFkoRjJ4NU[4Nlg6RC:jPh?=
DFCI76	MmqwRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		MnPmO\|IhcHK\|		M4C5bGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iRF\DTVc3KGOnbHzzJIV5eHKnc4PpcochTU2OND3BUGshVDFzNULSJI12fGGwdDDh[pRmeiB5MjDodpMh[nliQ3XscHRqfGW{LVfsc{BNfW2rbnXzZ4VvfCCFZXzsJHZq[WKrbHn0fUBCe3OjeTygSWM2OCB;IECuNFczKM7:TT6=	NFW3Sm49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkW2PFI5QSd-Mk[1OlgzQDl:L3G+
BAF3	MlfGRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?				NYHhOXd6SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBud3W\|ZTDCRWY{KGOnbHzzJIV5eHKnc4PpcochSUyNIFyxNVk3VSCvdYThcpQtKEOFNUCgQUAxNjB5NTFOwG0v	MkDUQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ{M{W5OFUoRjJ4MkO1PVQ2RC:jPh?=
BA/F3	MWTGeY5kfGmxbjDhd5NigQ>?		NVXFTGU2PzJiaILz		M3XIW2lvcGmkaYTpc44hd2ZiQVzLJGwyOTl4TTDteZRidnRiaX6gcY92e2ViQlGvSlMh[2WubIOgZZN{\XO\|ZXSgZZMhcW6qaXLpeIlwdiCxZjDj[YxtKHC{b3zp[oVz[XSrb36gZYZ1\XJiN{KgbJJ{KGK7IGfTWFEh[XO\|YYmsJGNEPTBiPTCwMlA4PSEQvF2u	NInX[Xc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkmyN\|Y6PSd-Mk[5NlM3QTV:L3G+
BA/F3	MWfGeY5kfGmxbjDhd5NigQ>?		MXi3NkBpenN?		MkXFTY5pcWKrdHnvckBw\iCHTVy0JIZ2e2WmIFHMT{BNOTF7Nl2gcZV1[W62IDj1cotvd3ewIH;ybYdqdiliZYjwdoV{e2WmIHnuJI1wfXOnIFLBM2Y{KGOnbHzzJIF{e2W\|c3XkJIF{KGOnbHyg[5Jwf3SqIHnubIljcXSrb36gcYVie3W{ZXSgZYZ1\XJiN{KgbJJ{KGK7IGPSRkBie3OjeTygR2M2OCB;IECuNFc2KM7:TT6=	MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzlzNUG2PUc,Ojd7MUWxOlk9N2F-
BA/F3	M{fuU2Z2dmO2aX;uJIF{e2G7		NHLrZpU4OiCqcoO=		NIXlRXpKdmirYnn0bY9vKG:oIFXNUFQh\nW\|ZXSgRWxMKCi3bnvuc5dvKG:{aXfpckkh\XiycnXzd4VlKGmwIH3veZNmKEKDL1[zJINmdGy\|IHHzd4V{e2WmIHHzJINmdGxiZ4Lve5RpKGmwaHnibZRqd25ibXXhd5Vz\WRiYX\0[ZIhPzJiaILzJIJ6KFOUQjDhd5NigSxiQ1O1NEA:KDBwMEe1JO69VS5?	NHe4[WI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{mxOVE3QSd-Mke5NVUyPjl:L3G+
BAF3	NVXPe3VTTnWwY4Tpc44h[XO\|YYm=		NEW4Xmw4OiCqcoO=		M3LaZmlvcGmkaYTpc44hd2ZiQVzLJGwyOTl4TTDteZRidnRiKIXub45wf25ib4Lp[4lvMSCneIDy[ZN{\WRiaX6gcY92e2ViQlHGN{Bk\WyuczDhd5Nme3OnZDDhd{Bk\WyuIHfyc5d1cCCrbnjpZol1cW:wIHHmeIVzKDd{IHjyd{BjgSCZU2StNUBie3OjeTygR2M2OCB;IECuNFc2KM7:TT6=	M2DGXFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6M{i1OVA2Lz5{OEO4OVUxPTxxYU6=
KARPAS299	NHfGU5RCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		Mkn5O\|IhcHK\|		NHvDNoNCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFvBVnBCWzJ7OTDj[YxteyCqYYLic5JqdmdiTmDNMWFNUyCjZoTldkA4OiCqcoOgZpkhW1KEIH;yJGNEUzhiYYPzZZktKEmFNUCgQUAxNjB6NDFOwG0v	NEnudlA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUK4PFk1OCd-MkmyPFg6PDB:L3G+
SMS-KCNR	NWexc41{SW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		MnTkO\|IhcHK\|		NF;ye25CdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIGPNV{1MS06UIHPlcIx{KGW6cILld5NqdmdiRV3MOE1CVEtiUkGyO\|VSKG23dHHueEBi\nSncjC3NkBpenNiYomgR4VtdFSrdHXyMWdtdyCOdX3pcoV{[2WwdDDD[YxtKF[rYXLpcIl1gSCDc4PhfUwhTUN3MDC9JFAvODl{IN88UU4>	NUXnR5I5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[1OlgzQDlpPkK2OVY5Ojh7PD;hQi=>
NCI-H3122	NGTiTYVCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		NGPKfFk4OiCqcoO=		MV7BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE6FST3IN\|EzOiClZXzsd{Bi\nSncjC3NkBpenNiYomgV3JDKG:{IFPDT\|gh[XO\|YYmsJGlEPTBiPTCwMlA6PiEQvF2u	MnnvQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl{OEi5OFAoRjJ7Mki4PVQxRC:jPh?=
NCI-H2228	MVvBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		M13GT\|czKGi{cx?=		NGXnbmtCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF7DTU1JOjJ{ODDj[YxteyCqYYLic5JqdmdiRV3MOE1CVEtiYX\0[ZIhPzJiaILzJIJ6KE2WVDDhd5NigSxiSVO1NEA:KDBwMEm5JO69VS5?	MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTF5NEiwPUc,OjlzN{S4NFk9N2F-
Ba/F3	MknSSpVv[3Srb36gZZN{[Xl?		M2\hOVczKGi{cx?=		NEj4T5hKdmirYnn0bY9vKG:oIFXNUFQuSUyNIF[xNVc1VCCvdYThcpQhMHWwa37ve44hd3KrZ3nuLUBmgHC{ZYPz[YQhcW5ibX;1d4UhSmFxRkOgZ4VtdHNiYYPz[ZN{\WRiYYOgZ4VtdCC4aXHibYxqfHliYX\0[ZIhPzJiaILzJIJ6KE2WUzDhd5NigSxiSVO1NEA:KDBwMUCxJO69VS5?	MlS5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ3NkiyPFkoRjJ4NU[4Nlg6RC:jPh?=
NCI-H2228	NIPidldEgXSxdH;4bYNqfHliYYPzZZk>		NVrMZoRjPzJiaILz		M1\1WGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG5EUS2KMkKyPEBk\WyuczDhd5Nme3OnZDDhd{Bk\WyuII\pZYJqdGm2eTDh[pRmeiB5MjDodpMh[nliTWTTJIF{e2G7LDDJR\|UxKD1iMD6xNFI3KM7:TT6=	NV63UZk1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW2OFQ3PzFpPkK1OlQ1PjdzPD;hQi=>
LAN5	M4LjUGFvfGmycn;sbYZmemG2aY\lJIF{e2G7		Ml6yO\|IhcHK\|		NITNb\|hCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFzBUlUh[2WubIOg[ZhxemW\|c3nu[{BGVUx2LVHMT{BTOTJ5NWGgcZV1[W62IHHmeIVzKDd{IHjyd{BjgSCFZXzsWIl1\XJvR3zvJGx2dWmwZYPj[Y51KEOnbHygWoli[mmuaYT5JGF{e2G7LDDFR\|UxKD1iMD6xNlIh\|ryPLh?=	NVX1fo02RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[1OlgzQDlpPkK2OVY5Ojh7PD;hQi=>
SU-DHL1	NW\lbWN5SW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		M4fDWVczKGi{cx?=		NU\D[JBQSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDTWU1FUExzIHPlcIx{KGijcnLvdolv\yCQUF2tRWxMKGGodHXyJFczKGi{czDifUBUWkJib4KgR2NMQCCjc4PhfUwhUUN3MDC9JFAvOTJ{IN88UU4>	M4e5d\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7Mki4PVQxLz5{OUK4PFk1ODxxYU6=
Kelly	MX\BcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		Mm\qO\|IhcHK\|		Mlm3RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCNZXzsfUBk\WyuczDlfJBz\XO\|aX7nJGVOVDRvQVzLJGYyOTd2TDDteZRidnRiYX\0[ZIhPzJiaILzJIJ6KEOnbHzUbZRmei2JbH:gUJVucW6nc3PlcpQhS2WubDDWbYFjcWyrdImgRZN{[XluIFXDOVAhRSByLkG0NkDPxE1w	NVfrSWo3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[1OlgzQDlpPkK2OVY5Ojh7PD;hQi=>
Ba/F3	NHHFVolHfW6ldHnvckBie3OjeR?=		NUH6dmtrPzJiaILz		MVHJcohq[mm2aX;uJI9nKEWPTEStRWxMKENzMUW2XUBufXSjboSgLJVvc26xd36gc5Jq\2mwKTDlfJBz\XO\|ZXSgbY4hdW:3c3WgRoEwTjNiY3XscJMh[XO\|ZYPz[YQh[XNiY3XscEB3cWGkaXzpeJkh[W[2ZYKgO\|IhcHK\|IHL5JG1VWyCjc4PhfUwhUUN3MDC9JFAvOTZ2IN88UU4>	MnTuQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ3NkiyPFkoRjJ4NU[4Nlg6RC:jPh?=
SH-SY5Y	NYrZXXh5SW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		NEDVW\|k4OiCqcoO=		MmfuRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCVSD3TXVV[KGOnbHzzJIV5eHKnc4PpcochTU2OND3BUGshTjFzN{TMJI12fGGwdDDh[pRmeiB5MjDodpMh[nliQ3XscHRqfGW{LVfsc{BNfW2rbnXzZ4VvfCCFZXzsJHZq[WKrbHn0fUBCe3OjeTygSWM2OCB;IECuNVg3KM7:TT6=	Ml\RQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ3NkiyPFkoRjJ4NU[4Nlg6RC:jPh?=
BAF3	M3;HVmFvfGmycn;sbYZmemG2aY\lJIF{e2G7		NEm2dFc4OiCqcoO=		MV7BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IH3veZNmKEKDRkOgZ4VtdHNiaHHyZo9zcW6pIFPEO\|QuWk:VMTDh[pRmeiB5MjDodpMh[nliU2LCJI9zKEOFS{igZZN{[XluIFnDOVAhRSByLkKzOEDPxE1w	MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTJ6OEm0NEc,Ojl{OEi5OFA9N2F-
SK-N-SH	NFu3d3RCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		MXO3NkBpenN?		NHjOPI1CdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIGPLMW4uW0hiY3XscJMh\XiycnXzd4lv\yCHTVy0MWFNUyCIMUG3OGwhdXW2YX70JIFnfGW{IEeyJIhzeyCkeTDD[YxtXGm2ZYKtS4xwKEy3bXnu[ZNk\W62IFPlcIwhXmmjYnnsbZR6KEG\|c3H5MEBGSzVyIE2gNE4{ODNizszNMi=>	NXX6UHp7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[1OlgzQDlpPkK2OVY5Ojh7PD;hQi=>
BAF3	NGfWZWZHfW6ldHnvckBie3OjeR?=		NVrCbG5jOiC2bzCzJIRigXN?		MVHJcohq[mm2aX;uJI9nKFSHTD3meZNm\CCrboP1cIlvKHKnY3XweI9zKCi3bnvuc5dvKG:{aXfpckkh\XiycnXzd4VlKGmwIH3veZNmKEKDRkOgZ4VtdHNiYX\0[ZIhOiC2bzCzJIRigXNiYomgcJVkcW[ncnHz[UBz\XCxcoTldkBo\W6nIHHzd4F6NCCLQ{WwJF0hOC5\|MUm1JO69VS5?	NUHGcoRFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO3OFIzPTJpPkKzO\|QzOjV{PD;hQi=>
BA/F3	MYPDfZRwfG:6aXPpeJkh[XO\|YYm=				MWLDfZRwfG:6aXPpeJkh[WejaX7zeEBud3W\|ZTDCRU9HOyClZXzsd{B1emGwc3\lZ5Rm\CC5aYToJHRmdC2LboPSJIdmdmViYYPz[ZN{\WRiYYOg[5Jwf3SqIHnubIljcXSrb36sJGlEPTBiPTCwMlMzKM7:TT6=	NIr6[Wc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{izO\|c6Pyd-MkO4N\|c4QTd:L3G+
SK-N-FI	NWLL[YZ4SW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		MoTEO\|IhcHK\|		M3WzNmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iU1utUk1HUSClZXzsd{BmgHC{ZYPzbY5oKHerbHSgeJlx\SCHTVy0MWFNUyCjZoTldkA4OiCqcoOgZpkhS2WubGTpeIVzNUeubzDMeY1qdmW\|Y3XueEBE\WyuIG\pZYJqdGm2eTDBd5NigSxiRVO1NEA:KDBwM{S5JO69VS5?	NV3kZZVbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[1OlgzQDlpPkK2OVY5Ojh7PD;hQi=>
CHLA20	NWrvVnJUSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		Ml2wO\|IhcHK\|		Mof3RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCFSFzBNlAh[2WubIOg[ZhxemW\|c3nu[{BGVUx2LVHMT{BTOTJ5NWGgcZV1[W62IHHmeIVzKDd{IHjyd{BjgSCFZXzsWIl1\XJvR3zvJGx2dWmwZYPj[Y51KEOnbHygWoli[mmuaYT5JGF{e2G7LDDFR\|UxKD1iMD6zOlMh\|ryPLh?=	MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjV4OEK4PUc,OjZ3NkiyPFk9N2F-
Ba/F3	MULGeY5kfGmxbjDhd5NigQ>?		NVrhd25VPzJiaILz		M1\CSWlvcGmkaYTpc44hd2ZiRV3MOE1CVEtiR{GyNFJTKG23dHHueEApfW6tbn;3ckBwemmpaX6pJIV5eHKnc4Pl[EBqdiCvb4Xz[UBD[S:IMzDj[YxteyCjc4Pld5Nm\CCjczDj[YxtKH[rYXLpcIl1gSCjZoTldkA4OiCqcoOgZpkhVVSVIHHzd4F6NCCLQ{WwJF0hOC52NESg{txONg>?	M3H0S\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4NU[4Nlg6Lz5{NkW2PFI5QTxxYU6=
LAN1	MlPZRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		NGLkcno4OiCqcoO=		MWXBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEyDTkGgZ4VtdHNiZYjwdoV{e2mwZzDFUWw1NUGOSzDGNVE4PExibYX0ZY51KGGodHXyJFczKGi{czDifUBE\WyuVHn0[ZIuT2yxIFz1cYlv\XOlZX70JGNmdGxiVnnhZoltcXS7IFHzd4F6NCCHQ{WwJF0hOC53NEmg{txONg>?	NV7KR5pYRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[1OlgzQDlpPkK2OVY5Ojh7PD;hQi=>
SK-N-BE(2)	MkTtRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		NIP6ZYU4OiCqcoO=		MkfuRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCVSz3OMWJGMDJrIHPlcIx{KGW6cILld5Nqdmdid3ns[EB1gXCnIFXNUFQuSUyNIHHmeIVzKDd{IHjyd{BjgSCFZXzsWIl1\XJvR3zvJGx2dWmwZYPj[Y51KEOnbHygWoli[mmuaYT5JGF{e2G7LDDFR\|UxKD1iMD61PVMh\|ryPLh?=	NYTzWHB1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[1OlgzQDlpPkK2OVY5Ojh7PD;hQi=>
Ba/F3	NYrCR5hbTnWwY4Tpc44h[XO\|YYm=		MmLHO\|IhcHK\|		NWjoemp[UW6qaXLpeIlwdiCxZjDFUWw1NUGOSzCxNVUyXGmwczDteZRidnRiKIXub45wf25ib4Lp[4lvMSCneIDy[ZN{\WRiaX6gcY92e2ViQnGvSlMh[2WubIOgZZN{\XO\|ZXSgZZMh[2WubDD2bYFjcWyrdImgZYZ1\XJiN{KgbJJ{KGK7IF3UV{Bie3OjeTygTWM2OCB;IECuOlY5KM7:TT6=	NVn0SVA6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[1OlgzQDlpPkK2OVY5Ojh7PD;hQi=>
BAF3	MV\BcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		M2fsUFczKGi{cx?=		MoGwRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDtc5V{\SCEQV[zJINmdGy\|IHjhdoJwemmwZzDFUWw1NUGOSzDHNVIxOlJibYX0ZY51KGGodHXyJFczKGi{czDifUBUWkJib4KgR2NMQCCjc4PhfUwhUUN3MDC9JFAvPzJ4IN88UU4>	MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTJ6OEm0NEc,Ojl{OEi5OFA9N2F-
Ba/F3	M1LkPWZ2dmO2aX;uJIF{e2G7		MniyO\|IhcHK\|		NUPkXVF{UW6qaXLpeIlwdiCxZjDoeY1idiCHR1\SJIRmdDF7L2S3PVBON0N5OUfTJI12fGGwdDDlfJBz\XO\|ZXSgbY4hdW:3c3WgRoEwTjNiY3XscJMh[XO\|ZYPz[YQh[XNiY3XscEBoem:5dHigbY5pcWKrdHnvckBi\nSncjC3NkBpenNiYomgR4VtdFSrdHXyMWdtdyCjc4PhfUwhT0l3MDC9JFAvPzhyNTFOwG0v	NES2dnc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUGzOlQ3PSd-MkmxN\|Y1PjV:L3G+
SK-N-AS	MVLBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		NFHNPVg4OiCqcoO=		M3jEfWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iU1utUk1CWyClZXzsd{BmgHC{ZYPzbY5oKHerbHSgeJlx\SCHTVy0MWFNUyCjZoTldkA4OiCqcoOgZpkhS2WubGTpeIVzNUeubzDMeY1qdmW\|Y3XueEBE\WyuIG\pZYJqdGm2eTDBd5NigSxiRVO1NEA:KDFwMES1JO69VS5?	NHXybFM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkW2PFI5QSd-Mk[1OlgzQDl:L3G+
BAF3	MWjDfZRwfG:6aXPpeJkh[XO\|YYm=		MlX4NkB1dyB\|IHThfZM>		NWixRoNCS3m2b4TvfIlkcXS7IHHnZYlve3RibX;1d4UhSkGIMzDj[YxteyCjZoTldkAzKHSxIEOg[IF6eyCkeTDseYNq\mW{YYPlJJJmeG:{dHXyJIdmdmViYYPzZZktKEmFNUCgQUAzNjR5NzFOwG0v	NH\De3Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{e0NlI2Oid-MkO3OFIzPTJ:L3G+
Ba/F3	NILnWINHfW6ldHnvckBie3OjeR?=		NGT2SGc4OiCqcoO=		MXTJcohq[mm2aX;uJI9nKEWPTEStRWxMKExzMUWyVkBufXSjboSgLJVvc26xd36gc5Jq\2mwKTDlfJBz\XO\|ZXSgbY4hdW:3c3WgRoEwTjNiY3XscJMh[XO\|ZYPz[YQh[XNiY3XscEB3cWGkaXzpeJkh[W[2ZYKgO\|IhcHK\|IHL5JG1VWyCjc4PhfUwhUUN3MDC9JFIvPzR5IN88UU4>	NGruPHA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkW2PFI5QSd-Mk[1OlgzQDl:L3G+
BA/F3	NUjNRlB7S3m2b4TvfIlkcXS7IHHzd4F6		MnXoO\|IhcHK\|		NGfmcnNEgXSxdH;4bYNqfHliYXfhbY5{fCCvb4Xz[UBDSS:IMzDj[YxteyCjc4Pld5Nm\CCjczDj[YxtKH[rYXLpcIl1gSCjZoTldkA4OiCqcoOgZpkhVVSVIHHzd4F6NCCLQ{WwJF0hPS53MUKg{txONg>?	NUC3e49SRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[1OlgzQDlpPkK2OVY5Ojh7PD;hQi=>
KARPAS299	NEXUcHBCeG:ydH;zbZMh[XO\|YYm=	M2\CVVYxKG6P	MmniNlQhcHK\|		NVTSSWc3UW6mdXP0bY9vKG:oIHHwc5B1d3OrczDpckBpfW2jbjDLRXJRSVN{OUmgZ4VtdHNiaHHyZo9zcW6pIF7QUU1CVEtiYYSgOlAhdk1iYX\0[ZIhOjRiaILzJIJ6KGGlcnnkbY5mKG:{YX7n[U9mfGirZHn1cUBjem:vaXTlJJN1[WmwaX7nJIJie2WmIH\seY9z\XOlZX7j[UBucWO{b4Pjc5Bq[yCvZYToc4Q>	MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTF5NEiwPUc,OjlzN{S4NFk9N2F-
SU-DHL1	NF3nZ3dHfW6ldHnvckBie3OjeR?=	NXToO\|IzOjBidH:gNlAxKG6P	NE\YSZYyKGi{		NIXmcGxKdmirYnn0bY9vKG:oIFHMT{BqdiCqdX3hckBUXS2GSFyxJINmdGy\|IHHzd4V{e2WmIHHzJJJm\HWldHnvckBqdiCVVFHUN{BxcG:\|cHjvdplt[XSrb36gZZQhYTdyNTDy[ZNq\HWnIHH0JFIxKHSxIEKwNEBvVSCjZoTldkAyKGi{IHL5JHdme3Sncn6gZoxwfCCjbnHsfZNqew>?	MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTJ6OEm0NEc,Ojl{OEi5OFA9N2F-
SU-DHL1	Mn\pSpVv[3Srb36gZZN{[Xl?	M1[wc\|IxKHSxIEKwNEBvVQ>?	M1LPNlEhcHJ?		MnLBTY5pcWKrdHnvckBw\iCDTFugdIhwe3Cqb4L5cIF1cW:wIHH0JHkyOjd6IILld4llfWViaX6gbJVu[W5iU2WtSGhNOSClZXzsd{BifCB{MDD0c{AzODBibl2gZYZ1\XJiMTDodkBjgSCZZYP0[ZJvKGKub4SgZY5idHm\|aYO=	NEjte\|U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUK4PFk1OCd-MkmyPFg6PDB:L3G+
NCI-H3122	MV3GeY5kfGmxbjDhd5NigQ>?	Ml;JNlAhfG9iMkCwJI5O	M2fSbFEhcHJ?		MkfiTY5pcWKrdHnvckBw\iCDTFugbY4hcHWvYX6gUmNKNUh\|MUKyJINmdGy\|IHHzd4V{e2WmIHHzJJJm\HWldHnvckBqdiCHUlugdIhwe3Cqb4L5cIF1cW:wIHH0JHQzODJxL2myNFQhemW\|aXT1[ZMh[XRiMkCgeI8hOjByIH7NJIFnfGW{IEGgbJIh[nliV3XzeIVzdiCkbH;0JIFv[Wy7c3nz	MmXlQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl{OEi5OFAoRjJ7Mki4PVQxRC:jPh?=
NCI-H3122	M{XvdGZ2dmO2aX;uJIF{e2G7	MkTBNlAhfG9iMkCwJI5O	MlPPNUBpeg>?		MkPjTY5pcWKrdHnvckBw\iCDTFugbY4hcHWvYX6gUmNKNUh\|MUKyJINmdGy\|IHHzd4V{e2WmIHHzJJJm\HWldHnvckBqdiCDa4SgdIhwe3Cqb4L5cIF1cW:wIHH0JHM1PzNicnXzbYR2\SCjdDCyNEB1dyB{MECgcm0h[W[2ZYKgNUBpeiCkeTDX[ZN1\XKwIHLsc5Qh[W6jbInzbZM>	MoP1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl{OEi5OFAoRjJ7Mki4PVQxRC:jPh?=
SU-DHL1	M{XNeGZ2dmO2aX;uJIF{e2G7	MnLwNlAhfG9iMkCwJI5O	M{XITFEhcHJ?		MYLJcohq[mm2aX;uJI9nKEGOSzDpckBpfW2jbjDTWU1FUExzIHPlcIx{KGG\|c3Xzd4VlKGG\|IILl[JVkfGmxbjDpckBCc3RicHjvd5Bpd3K7bHH0bY9vKGG2IGO0O\|MhemW\|aXT1[UBifCB{MDD0c{AzODBibl2gZYZ1\XJiMTDodkBjgSCZZYP0[ZJvKGKub4SgZY5idHm\|aYO=	M{XHPFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7Mki4PVQxLz5{OUK4PFk1ODxxYU6=
SU-DHL1	NFPKNI9HfW6ldHnvckBie3OjeR?=	NEH0TXYzOCC2bzCyNFAhdk1?	MnPUNUBpeg>?		MlW2TY5pcWKrdHnvckBw\iCDTFugbY4hcHWvYX6gV3UuTEiOMTDj[YxteyCjc4Pld5Nm\CCjczDy[YR2[3Srb36gbY4hTVKNIIDoc5NxcG:{eXzheIlwdiCjdDDUNlAzNy:\MkC0JJJme2mmdXXzJIF1KDJyIITvJFIxOCCwTTDh[pRmeiBzIHjyJIJ6KFenc4Tldo4h[myxdDDhcoFtgXOrcx?=	M3jVbFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7Mki4PVQxLz5{OUK4PFk1ODxxYU6=
NCI-H3122	MVrGeY5kfGmxbjDhd5NigQ>?	MUiyNEB1dyB{MECgcm0>	M1rjOFEhcHJ?		MoLkTY5pcWKrdHnvckBw\iCDTFugdIhwe3Cqb4L5cIF1cW:wIHH0JHkyOjd6IILld4llfWViaX6gbJVu[W5iTlPJMWg{OTJ{IHPlcIx{KGG2IEKwJJRwKDJyMDDuUUBi\nSncjCxJIhzKGK7IGfld5Rmem5iYnzveEBidmGueYPpdy=>	MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTJ6OEm0NEc,Ojl{OEi5OFA9N2F-
NCI-H3122	MYLGeY5kfGmxbjDhd5NigQ>?	NV;VVlFpOjBidH:gNlAxKG6P	NXPTbXRyOSCqch?=		MVTJcohq[mm2aX;uJI9nKEGOSzDpckBpfW2jbjDOR2kuUDNzMkKgZ4VtdHNiYYPz[ZN{\WRiYYOgdoVlfWO2aX;uJIlvKFOWQWSzJJBpd3OyaH;yfYxifGmxbjDheEB[PzB3IILld4llfWViYYSgNlAhfG9iMkCwJI5OKGGodHXyJFEhcHJiYomgW4V{fGW{bjDicI91KGGwYXz5d4l{	M2D3O\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7Mki4PVQxLz5{OUK4PFk1ODxxYU6=
SU-DHL1	MkSxSpVv[3Srb36gZZN{[Xl?	MYGzNEBvVQ>?	MlHpNVYhcHK\|		NYPlbm1CUW6qaXLpeIlwdiCxZjDBUGsh[XW2b4Doc5NxcG:{eXzheIlwdiCjdDDZNVUxPyC{ZYPp[JVmKGmwIHj1cYFvKFOXLVTIUFEh[2WubIOgZZQhOzBibl2gZYZ1\XJiMU[gbJJ{KGK7IGfld5Rmem5iYnzveEBidmGueYPpdy=>	NUixVZpuRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm2Nlc4OjVpPkK5OlI4PzJ3PD;hQi=>
SU-DHL1	Mn3USpVv[3Srb36gZZN{[Xl?	NWPySoVzOzBibl2=	MVKxOkBpenN?		NFPOS2VKdmirYnn0bY9vKG:oIFHMT{BqdiCqdX3hckBUXS2GSFyxJINmdGy\|IHHzd4V{e2WmIHHzJJJm\HWldHnvckBqdiCVVFHUN{BxcG:\|cHjvdplt[XSrb36gZZQhYTdyNTDy[ZNq\HWnIHH0JFMxKG6PIHHmeIVzKDF4IHjyd{BjgSCZZYP0[ZJvKGKub4SgZY5idHm\|aYO=	NX7JeolmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm2Nlc4OjVpPkK5OlI4PzJ3PD;hQi=>
NCI-H3122	MX;GeY5kfGmxbjDhd5NigQ>?	MoD6OVAhfG9iMkWwJI5O	NHS5bnQyPiCqcoO=		MlTkTY5lfWO2aX;uJI9nKEGOSzDk[Ydz[WSjdHnvckBqdiCqdX3hckBPS0lvSEOxNlIh[2WubIOgZZN{\XO\|ZXSgZZMh\GWlcnXhd4UhcW5iQVzLJJBpd3OyaH;yfYxifGmxbjDheEB[OTZyNDDheEA2OCC2bzCyOVAhdk1iYX\0[ZIhOTZiaILzJIJ6KGmvbYXuc4Jtd3RibXX0bI9l	M1e2ZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7Nk[wPVg1Lz5{OU[2NFk5PDxxYU6=
SH-SY5Y	MYPBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		NIjhboE4OiCqcoO=		MWLBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKFOKLWPZOXkh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IFPlcIxVcXSncj3HcI8hdHWvaX7ld4NmdnRiY3XscEB3cWGkaXzpeJkh[XO\|YYm=	MlTHQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl4NkC5PFQoRjJ7Nk[wPVg1RC:jPh?=
CHLA20	M3Lk[GFvfGmycn;sbYZmemG2aY\lJIF{e2G7		NUHKT2Z{PzJiaILz		Ml7PRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCFSFzBNlAh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IFPlcIxVcXSncj3HcI8hdHWvaX7ld4NmdnRiY3XscEB3cWGkaXzpeJkh[XO\|YYm=	MnfqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl4NkC5PFQoRjJ7Nk[wPVg1RC:jPh?=
SH-SY5Y	M1TOfGFvfGmycn;sbYZmemG2aY\lJIF{e2G7		MXy3NkBpenN?		M2CzbmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iU1itV3k2YSClZXzsd{Bi\nSncjC3NkBpenNiaX6gdJJme2WwY3Wgc4YhSUKFQkGgbY5pcWKrdH;yJJRiemmzdXnkZZIh[nliQ3XscHRqfGW{LVfsc{BtfW2rbnXzZ4VvfCClZXzsJJZq[WKrbHn0fUBie3OjeR?=	NFnrUVI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OU[2NFk5PCd-Mkm2OlA6QDR:L3G+
KARPAS299	NGTHTYdHfW6ldHnvckBie3OjeR?=	MYS1NEB1dyB{NUCgcm0>	MWCxOkBpenN?		NISyOIJKdmS3Y4Tpc44hd2ZiQVzLJIRm\3KjZHH0bY9vKGmwIHj1cYFvKEuDUmDBV\|I6QSClZXzsd{Bie3Onc4Pl[EBieyCmZXPy[YF{\SCrbjDBUGsheGixc4Doc5J6dGG2aX;uJIF1KFlzNkC0JIF1KDVyIITvJFI2OCCwTTDh[pRmeiBzNjDodpMh[nliaX3teY5w[myxdDDt[ZRpd2R?	M2T6[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7Nk[wPVg1Lz5{OU[2NFk5PDxxYU6=
CHLA20	NUn2ZmdFSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		M2LGeVczKGi{cx?=		MlTuRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCFSFzBNlAh[2WubIOgZYZ1\XJiN{KgbJJ{KGmwIIDy[ZNmdmOnIH;mJGFDS0JzIHnubIljcXSxcjD0ZZJqeXWrZHHyJIJ6KEOnbHzUbZRmei2JbH:gcJVucW6nc3PlcpQh[2WubDD2bYFjcWyrdImgZZN{[Xl?	NU\sZW5nRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm2OlA6QDRpPkK5OlYxQTh2PD;hQi=>
NCI-H3122	MojORY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		MmLBO\|IhcHK\|		Mn;CRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCQQ1mtTFMyOjJiY3XscJMh[W[2ZYKgO\|IhcHK\|IHL5JGNmdGyWaYTldk1IdG9ibIXtbY5me2OnboSgZ4VtdCC4aXHibYxqfHliYYPzZZk>	NHrRb4U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OU[2NFk5PCd-Mkm2OlA6QDR:L3G+
KARPAS299	NWrlNZBwSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		M{joRlczKGi{cx?=		M1ztcmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iS1HSVGFUOjl7IHPlcIx{KGGodHXyJFczKGi{czDifUBE\WyuVHn0[ZIuT2yxIHz1cYlv\XOlZX70JINmdGxidnnhZoltcXS7IHHzd4F6	NGXQe\|M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OU[2NFk5PCd-Mkm2OlA6QDR:L3G+
SU-DHL1	MkLyRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		MnywO\|IhcHK\|		NHnLZW9CdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIGPVMWRJVDFiY3XscJMh[W[2ZYKgO\|IhcHK\|IHL5JGNmdGyWaYTldk1IdG9ibIXtbY5me2OnboSgZ4VtdCC4aXHibYxqfHliYYPzZZk>	Mnf3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl4NkC5PFQoRjJ7Nk[wPVg1RC:jPh?=
KARPAS299	MmnkRZBweHSxc3nzJIF{e2G7	MVu1NEBvVQ>?	MoPMNlQhcHK\|		MUXJcoR2[3Srb36gc4Yh[XCxcITvd4l{KGmwIHj1cYFvKEuDUmDBV\|I6QSClZXzsd{Bie3Onc4Pl[EBieyC3bnPs[YFzKGOnbHygd4hzcW6tYXflJIF1KDVyIH7NJIFnfGW{IEK0JIhzeyCkeTDIc4VkcHO2IEOzNlU5KHO2YXnubY5oKGKjc3XkJIlvfmW{dHXkJIZtfW:{ZYPj[Y5k\SCvaXPyc5Nkd3C7	NXL6TnNCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{CyNlMyOjBpPkOwNlI{OTJyPD;hQi=>
KARPAS299	MWfBdI9xfG:\|aYOgZZN{[Xl?	MnPkOVAhdk1?	NV;RSGhJOjRiaILz		MlXuTY5lfWO2aX;uJI9nKGGyb4D0c5NqeyCrbjDoeY1idiCNQWLQRXMzQTliY3XscJMh[XO\|ZYPz[YQh[XNibHH0[UBieG:ydH;0bYMh[2WubIOgZZQhPTBibl2gZYZ1\XJiMkSgbJJ{KGK7IFHPM2VDKGSxdXLs[UB{fGGrbnnu[{Bj[XOnZDDpcpZmenSnZDDmcJVwemW\|Y3XuZ4UhdWmlcn;zZ49xgQ>?	MofBQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzB{MkOxNlAoRjNyMkKzNVIxRC:jPh?=
KARPAS299	MlfsRZBweHSxc3nzJIF{e2G7	M1PSdlUxKG6P	MVqyOEBpenN?		Mk\mTY5lfWO2aX;uJI9nKGGyb4D0c5NqeyCrbjDoeY1idiCNQWLQRXMzQTliY3XscJMh[XO\|ZYPz[YQh[XNiZoLh[41mdnSjdHnvckBifCB3MDDuUUBi\nSncjCyOEBpenNiYomgTI9m[2i\|dDCzN\|I2QCC\|dHHpcolv\yCkYYPl[EBqdn[ncoTl[EBndHWxcnXzZ4Vv[2VibXnjdo9{[2:yeR?=	NFfFVHU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9\|MEKyN\|EzOCd-M{CyNlMyOjB:L3G+

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	p-ALK / ALK / p-AKT / AKT / p-ERK / ERK; PubMed: 28425916 eLife Inhibition of ALK autophosphorylation and downstream signaling by ceritinib, crizotinib and PF06463922 in NB-1 cells. Cells were harvested after treatment for 4 hr with the indicated compounds at different concentrations. Whole cell lysates were analyzed by Western blotting to detect the levels of ALK, AKT and ERK proteins and their phosphorylation. pROS1 / ROS1 / pSTAT3 / STAT3 ; PubMed: 25351743 Clin Cancer Res Inhibition of phospho-ROS1 by various ALK inhibitors in Ba/F3 models. CD74-ROS1 expressing Ba/F3 cells were exposed to increasing concentrations of crizotinib, ceritinib, AP26113, or ASP3026 for 3 h. Cell lysates were immunoblotted to detect the indicated proteins.	28425916 25351743
Growth inhibition assay	Cell viability; PubMed: 29067644 Target Oncol The effects of ceritinib treatment on cell viability in ARMS and ERMS cell lines. Cells were treated with 0-5 μM ceritinib for 72 h (Rh30, RD), 120 h (Rh41), or 144 h (Rh18, Aska) and cell viability was assessed. The y-axis represents relative cell viability compared to non-treated cells (control). Effects on cell viability were determined in triplicate. Values are presented as mean ± SD. Dotted line represents the IC50-value. The human synovial sarcoma cell line Aska with constitutive ALK phosphorylation was used as a positive control.	29067644

体内研究

LDK378 用于降低形成反应代谢的可能性，在肝微粒体几乎检测不到谷胱甘肽（GSH）加合物的水平（<1％）。LDK378具有相对良好的代谢稳定性，中度抑制CYP3A4（Midazolam底物）和抑制hERG。LDK378处理动物，与肝脏血流量相比，具有低的血浆清除率（小鼠，大鼠，狗和猴），处理小鼠，大鼠，狗和猴的口服生物利用度都在55％以上。LDK378 处理Karpas299 和H2228 大鼠移植瘤模型，抑制肿瘤生长，诱导肿瘤衰退，这种作用具有剂量依赖性，体重没有降低。LDK378处理小鼠，剂量高达100 mg/kg，对胰岛素水平或血浆葡萄糖的利用无影响。^[1]

激酶实验：^[1]	- 合并激酶分析: 所有激酶使用杆状病毒表达技术表达为组氨酸或GST标签的融合蛋白，除了在大肠杆菌中产生的未标记的ERK2。在LabChip迁移实验中测量激酶活性。实验在30°C下进行60分钟。在有或无LDK378存在时，通过线性进展曲线，获得LDK378对酶活性的作用效果。
细胞实验：^[1]	- 合并 Cell lines: Ba/F3-NPM-ALK, Ba/F3-Tel-InsR, Ba/F3-WT, Karpas299 细胞 Concentrations: ~100 μM Incubation Time: 2-3 天 Method: 表达荧光素酶的细胞与连续稀释的LDK378 或 DMSO 温育2-3天。荧光素酶的表达用来衡量细胞增殖/存活，使用Bright-Glo萤光素酶检测系统来评估。使用 XLFit软件获得 IC50值。 (Only for Reference)
动物实验：^[1]	- 合并 Animal Models: 携带 Karpas299/H2228肿瘤的 RNU裸鼠 Dosages: ~50 mg/kg Administration: 口服饲喂 (Only for Reference)

参考文献

[1] Marsilje TH, et al. J Med Chem. 2013, Jun 6.

溶解度 (25°C)

体外	DMSO	20 mg/mL warmed (35.83 mM)
	Ethanol	3 mg/mL (5.37 mM)
	Water	Insoluble

* 溶解度检测是由Selleck技术部门检测的，可能会和文献中提供的溶解度有所差异，这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据 Download Ceritinib (LDK378) SDF

分子量	558.14
化学式	C₂₈H₃₆ClN₅O₃S
CAS号	1032900-25-6
储存条件	3年-20°C 粉状 2年-80°C 溶于溶剂
别名	N/A

动物体内配方计算器 (澄清溶液)

第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量）

给药剂量

mg/kg

动物平均体重

每只动物给药体积

动物数量

只

第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系Selleck为您提供正确的澄清溶液配方）

% DMSO+ % + % Tween 80+ % ddH₂O

计算重置

计算结果:

工作液浓度： mg/ml；

DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，注：如该浓度超过该批次药物DMSO溶解度，请先联系Selleck）；

体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL ddH₂O，混匀澄清。

注意：1. 首先保证母液是澄清的；
2. 一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。

计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系，公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

质量

浓度

体积

分子量
=

×

×

*在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。

稀释计算器

用本工具协助配置特定浓度的溶液，使用的计算公式为：

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入输出 )

C1

V1

C2

V2
×

=

×

在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。.

连续稀释计算器方程

连续稀释
初始浓度:
稀释倍数:

计算结果

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

分子量计算器

通过输入化合物的化学式来计算其分子量：

注：化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量	浓度	体积	分子量
=	×	×
计算

临床试验信息 (data from https://clinicaltrials.gov, updated on 2021-01-06)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT02450903	Completed	Drug: LDK378	Non-Small-Cell Lung Cancer	Novartis Pharmaceuticals\|Novartis	August 21 2015	Phase 2
NCT02040870	Completed	Drug: LDK378	Non-Small Cell Lung Cancer	Novartis Pharmaceuticals\|Novartis	March 7 2014	Phase 1\|Phase 2
NCT01950481	Completed	Drug: LDK378	Normal Hepatic Function\|Impaired Hepatic Function	Novartis Pharmaceuticals\|Novartis	January 2014	Phase 1
NCT01772797	Completed	Drug: LDK378\|Drug: AUY922	Anaplastic Lymphoma Kinase (ALK)\|Non-small Cell Lung Cancer	Novartis Pharmaceuticals\|Novartis	June 2013	Phase 1
NCT01685060	Completed	Drug: LDK378	Non-Small Cell Lung Cancer	Novartis Pharmaceuticals\|Novartis	November 26 2012	Phase 2
NCT01634763	Completed	Drug: LDK378	Tumors Characterized by Genetic Alterations in Anaplastic Lymphoma Kinase (ALK)	Novartis Pharmaceuticals\|Novartis	June 2012	Phase 1

技术支持

在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题，请给我们留言。

常见问题及建议解决方法

问题 1：
how to reconstitute the inhibitor for oral administration to mice?
回答：
You can resuspend LDK378 in 30% PEG400/0.5% Tween 80/5% propylene glycol and use the suspension for oral gavage feeding.

ALK Signaling Pathway Map

ALK Inhibitors with Unique Features

非特异性的ALK抑制剂

GSK1838705A : IGF-1R, IC50=2.0 nM; IR, IC50=1.6 nM, ALK, IC50=0.5 nM.
FDA批准的ALK抑制剂

Crizotinib (PF-02341066) : Approved by FDA for non-small cell lung carcinoma (NSCLC).
最新的ALK抑制剂

ASP3026 ^New : Novel and selective inhibitor for ALK with IC50 of 3.5 nM.
经典的ALK抑制剂

TAE684 (NVP-TAE684) : Potent and selective ALK inhibitor with IC50 of 3 nM, 100-fold more sensitive for ALK than InsR.

研究领域

产品类型

定制您的化合物库

Ceritinib (LDK378)

客户使用Selleck生产的Ceritinib (LDK378)发表文献64篇：

产品安全说明书

ALK抑制剂选择性比较

生物活性

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

参考文献

溶解度 (25°C)

化学数据 Download Ceritinib (LDK378) SDF

动物体内配方计算器 (澄清溶液)

计算器

摩尔浓度计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

稀释计算器

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

连续稀释计算器方程

连续稀释

计算结果

分子量计算器

总分子量：g/mol

摩尔浓度计算器

临床试验信息 (data from https://clinicaltrials.gov, updated on 2021-01-06)

技术支持

常见问题及建议解决方法

ALK Signaling Pathway Map

ALK Inhibitors with Unique Features

相关ALK产品